Comparison of the Treatment Efficacy of Rituximab and Plasmapheresis/Intravenous Immunoglobulin Combination with Historical Control in Chronic Antibody Mediated Rejection

RUHİ B. Ç., Tuğcu M., Kasapoğlu U., Gökçe A. M., ATA P., TİTİZ M. İ.

TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, vol.26, no.1, pp.48-54, 2017 (Peer-Reviewed Journal) identifier identifier


OBJECTIVE: Chronic antibody mediated rejection (CAMR) is a major therapeutic challenge for achieving long-term graft survival; treatment options are limited to several anti-humoral interventions.